Status:
COMPLETED
Treatment of Vasomotor Symptoms in Korean Post Menopausal Women
Lead Sponsor:
Bayer
Conditions:
Vasomotor Symptoms
Eligibility:
FEMALE
45-65 years
Phase:
PHASE3
Brief Summary
Study to demonstrate that the therapeutic efficacy of Angeliq® is better than placebo in Korean postmenopausal women with hot flushes and other climacteric symptoms. Safety and tolerability of Angeliq...
Eligibility Criteria
Inclusion
- Postmenopausal Korean women suffering from hot flushes
Exclusion
- Standard exclusion criteria for HRT clinical trials had to be obeyed, including current or history of hormone dependent malignant disease, thromboembolic disorders, abnormal cervical smear, undiagnosed vaginal bleeding.
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2005
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00651599
Start Date
July 1 2004
End Date
May 1 2005
Last Update
December 31 2014
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul, South Korea, 110-744
2
Seoul, South Korea, 135-710
3
Seoul, South Korea, 138-736
4
Seoul, South Korea